StreetInsider.com News Articles

Form 8-K Azitra, Inc. For: Sep 08

Tue, 08 Sep 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260908/27033657.html

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

BRANFORD, Conn., Sept. 8, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph.D., MPH, Azitra's Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City.

Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

Form 8-K Azitra, Inc. For: Aug 21

Fri, 21 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26958638.html

Form 8-K Azitra, Inc. For: Aug 21

Fri, 21 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26958638.html

Azitra regains NYSE American listing compliance

Fri, 21 Aug 2026 08:00:58 -0400

Azitra, Inc. (NYSE American: AZTR) announced it received written notification from NYSE American LLC confirming the company has regained compliance with all continued listing standards set forth in Part 10 of the NYSE American Company Guide.

In a letter dated Aug. 19, 2026, NYSE Regulation informed Azitra that the company resolved previously disclosed listing deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. As a result, the "below compliance" indicator will no longer be disseminated, and Azitra will be removed from NYSE American's list of noncompliant issuers.

The company will remain subject to NYSE Regulation's continued listing monitoring procedures.

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Fri, 21 Aug 2026 08:00:00 -0400

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26931989.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26931989.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Partners Limited Partnership

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931847.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Nantahala Capital Partners Limited Partnership

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931847.html

Azitra, Inc. (AZTR) Tops Q2 EPS by 54c

Thu, 13 Aug 2026 09:32:04 -0400

Azitra, Inc. (NYSE: AZTR) reported Q2 EPS of ($0.17), $0.54 better than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Azitra, Inc. (AZTR) click here.

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates